Level Chart

Basic Info

Vertex Pharmaceuticals Inc (VRTX) - Trikafta / Kaftrio Revenue is at a current level of 2.572B, down from 2.654B last quarter and down from 2.721B one year ago. This is a change of -3.06% from last quarter and -5.45% from one year ago.

Region United States
Source Fiscal.ai

Data provided via Fiscal.ai

Stats

Last Value 2.572B
Latest Period Dec 2025
Last Updated Mar 23 2026, 14:15 EDT
Next Release Apr 15 2026, 08:30 EDT (E)
Average Growth Rate 37.46%
Value from Last Quarter 2.654B
Change from Last Quarter -3.06%
Value from 1 Year Ago 2.721B
Change from 1 Year Ago -5.45%
Frequency Quarterly
Unit USD
Adjustment N/A
Download Source File

Historical Data

View and export this data back to 2019. Upgrade now.
Date Value
December 31, 2025 2.572B
September 30, 2025 2.654B
June 30, 2025 2.551B
March 31, 2025 2.536B
December 31, 2024 2.721B
September 30, 2024 2.585B
June 30, 2024 2.449B
March 31, 2024 2.484B
December 31, 2023 2.333B
September 30, 2023 2.274B
June 30, 2023 2.240B
March 31, 2023 2.097B
December 31, 2022 2.022B
Date Value
September 30, 2022 2.010B
June 30, 2022 1.893B
March 31, 2022 1.762B
December 31, 2021 1.693B
September 30, 2021 1.556B
June 30, 2021 1.256B
March 31, 2021 1.193B
December 31, 2020 1.091B
September 30, 2020 960.00M
June 30, 2020 918.00M
March 31, 2020 895.00M
December 31, 2019 420.00M

Basic Info

Vertex Pharmaceuticals Inc (VRTX) - Trikafta / Kaftrio Revenue is at a current level of 2.572B, down from 2.654B last quarter and down from 2.721B one year ago. This is a change of -3.06% from last quarter and -5.45% from one year ago.

Region United States
Source Fiscal.ai

Data provided via Fiscal.ai

Stats

Last Value 2.572B
Latest Period Dec 2025
Last Updated Mar 23 2026, 14:15 EDT
Next Release Apr 15 2026, 08:30 EDT (E)
Average Growth Rate 37.46%
Value from Last Quarter 2.654B
Change from Last Quarter -3.06%
Value from 1 Year Ago 2.721B
Change from 1 Year Ago -5.45%
Frequency Quarterly
Unit USD
Adjustment N/A
Download Source File

Related Securities

Symbol Name Change %
VRTX Vertex Pharmaceuticals, Inc. -1.82%